Sector News

UCB spins out neuro startup with €17M from Novo, Johnson & Johnson

February 8, 2018
Life sciences

UCB has licensed a small molecule program for cognitive disorders to Syndesi Therapeutics, which launched Thursday with a €17 million ($20.9 million) investment from the likes of V-Bio Ventures and the venture arms of Novo Nordisk and Johnson & Johnson.

Syndesi has an exclusive license from UCB to develop and commercialize a group of molecules that modulate the synaptic vesicle protein SV2A, which is involved in transmitting impulses between neurons in the brain.

The startup will look into the potential of these molecules in the treatment of Alzheimer’s disease, as well as other dementias and schizophrenia-linked cognitive impairment.

“Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimer’s Disease and other indications characterized by cognitive impairment,” said Jonathan Savidge, Syndesi CEO, in the statement. “Syndesi benefits both from UCB’s research expertise and from an impressive syndicate of experienced investors and their respective networks.”

The series A round, led by Novo Seeds and Fountain Healthcare, will support the clinical development of the lead candidate up to early proof of concept in humans.

Syndesi is based at the Centre d’Entreprises et d’Innovation in Louvain-la-Neuve, Belgium, and has space at Johnson & Johnson’s JLINX incubator in Beerse. But the incubator is getting a makeover—launched in March 2016 as a collaboration between Janssen and Bioqube Ventures, JLINX will transition into a JLABS site, the first such site in Europe.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.